Immunotherapy prototype Mark 3.0 model in primary liver cancer:adding locoregional stereotactic therapy and prognostic factors classification management  

作　　者：Xu Yang Nan Zhang Yang Song Xiaobo Yang Xinting Sang Haitao Zhao 

机构地区：[1]Department of Liver Surgery,State Key Laboratory of Complex Severe and Rare Diseases,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing,China [2]Department of Liver Surgery,State Key Laboratory of Complex Severe and Rare Diseases,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College(CAMS&PUMC),Beijing 100730,China

出　　处：《Medical Review》2022年第6期547-552,共6页医学评论（英文）

基　　金：supported by National High Level Hospital Clinical Research Funding[2022-PUMCH-B-128],CAMS Innovation Fund for Medical Sciences(CIFMS)[2022-I2M-C&T-A-003][2021-I2M-1-061][2021-I2M-1-003];CSCO-hengrui Cancer Research Fund[Y-HR2019-0239][Y-HR2020MS-0415][Y-HR2020QN-0414];CSCO-MSD Cancer Research Fund[Y-MSDZD2021-0213]and National Ten-Thousand Talent Program.

摘　　要：Immune checkpoint inhibitors(ICIs)like programmed cell death-1(PD-1)/programmed death-ligand 1(PD-L1)inhibitor have shown considerable efficacy in several important cancers including primary liver cancer(PLC)like hepatocellular carcinoma and cholangiocarcinoma.However,only some patients with PLC will benefit,so combination therapy and biomarker classification detected by next-generation sequencing or immunohistochemistry are very important.Herein,we briefly summarize ICI-based therapies and stratify these evolving therapies for advanced PLC into three stages of immunotherapies Mark(Mk.)1.0,2.0,and 3.0.We illustrated the significance of ICI monotherapy(Mk.1.0),offering combinational approaches with traditional strategies(Mk.2.0)and additional locoregional therapy(Mk.3.0)to achieve longer survival and even meet the“No Evidence of Disease”status.We also highlight the importance of biomarkers and prognostic factors for patients with advanced PLC treated with ICI-based therapies.Multidisci-plinary team management should be investigated and collaborated closely to manage adverse events and sequential therapy suggestions for patients.

关 键 词：hepatocellular carcinoma immune checkpoint inhibitors primary liver cancer prognostic factors programmed cell death-1 stereotactic therapy 

分 类 号：R730.51[医药卫生—肿瘤]